Xiamen Amoytop Biotech Co., Ltd.
Clinical trials sponsored by Xiamen Amoytop Biotech Co., Ltd., explained in plain language.
-
Could a simple injection prevent preeclampsia? early trial begins
Disease control CompletedThis early-stage trial tested the safety and tolerability of telpegfilgrastim injections in 18 non-pregnant women, including some with a history of preeclampsia. Researchers monitored side effects, drug levels in the blood, and immune markers. The goal is to see if the drug is sa…
Phase: PHASE1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 23, 2026 22:18 UTC
-
New drug for fatty liver disease first tested in healthy volunteers
Knowledge-focused CompletedThis early-stage study tested the safety of a new drug called ACT500 in 72 healthy Chinese adults. Participants received either the drug or a placebo, and researchers monitored side effects and how the drug moved through the body. The goal was not to treat disease but to gather e…
Phase: PHASE1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:52 UTC